S1P-205 is under clinical development by S1 Biopharma and currently in Phase II for Erectile Dysfunction. According to GlobalData, Phase II drugs for Erectile Dysfunction have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how S1P-205’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
S1P-205 overview
S1P-205, a fixed dose combination of bupropion hydrochloride and trazodone hydrochloride is under development for the treatment of erectile dysfunction. It is administered orally. It works both as a standalone and as an adjunct to testosterone therapy for HSDD. Bupropion hydrochloride targets norepinephrine and dopamine transporters and trazodone hydrochloride targets serotonin transporter and 5-HT2A, 5-HT2C receptors. It was also under development for the treatment of male hypoactive sexual desire disorder (HSDD).
S1 Biopharma overview
S1 Biopharma is a clinical-stage biopharmaceutical company that develops therapies for sexual dysfunction in humans. The company products include Lorexys for hypoactive sexual desire disorder in women, Orexa erectile dysfunction, S1B-307 orgasmic disorder, and S1B-3006 treatment-resistant cases of sexual dysfunction in men and women. The company’s non-hormonal therapies are used to restore the natural balance of neurotransmitters in the brain.S1 Biopharma’s products are designed to treat individuals suffering from various forms of sexual dysfunction which include men and women. S1 Biopharma is headquartered in New York, the US.
For a complete picture of S1P-205’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
